作用于垂体治疗库欣病的药物研究进展

doi:10.12114/j.issn.1007-9572.2021.01.039

摘要/Abstract

摘要： 由垂体促肾上腺皮质激素腺瘤分泌过多的促肾上腺皮质激素（ACTH）所致的库欣综合征又称为库欣病，其首选治疗方式为手术切除垂体腺瘤，但部分患者术后治疗效果欠佳或无法进行手术，药物治疗作为二线治疗，也是必不可少的治疗手段。近年来对库欣病发病机制的研究得到了很大进展，作用于垂体促肾上腺皮质激素腺瘤的药物既能控制肿瘤增殖也能抑制ACTH分泌，为库欣病的药物治疗奠定了理论和临床实践基础。本文致力于论述垂体促肾上腺皮质激素腺瘤导向药物及其相应作用机制，以期进一步加深对库欣病治疗的了解，为制订更有效的治疗策略提供理论参考。

关键词: 库欣综合征, 促肾上腺皮质激素, 药物疗法, 综述

Abstract:

Cushing's disease is caused by excessive secretion of adrenocorticotropic hormone (ACTH) by hormone-secreting pituitary adenomas, the first-choice treatment for which is surgical resection of the pituitary adenoma. Medication therapy is the second-line treatment, and a necessary treatment for some patients with unsatisfactory surgical results or failing to use the surgery. With recent developments in pathogenesis studies of Cushing's disease, medications specifically targeting hormone-secreting pituitary adenomas have proven to be effective in controlling the tumor growth, and suppressing the tumor's secretion of ACTH, which may be a theoretical and practical basis for medical treatment of Cushing's disease. In this review, we discussed pituitary-directed medical therapies for Cushing's disease and their mechanisms of actions, aiming to increase medical workers' understanding of this disease, and to offer theoretical evidence for the development of appropriate treatment strategies.

Key words: Cushing syndrome, Adrenocorticotropic hormone, Drug therapy, Review

李玲,张会娟. 作用于垂体治疗库欣病的药物研究进展[J]. 中国全科医学, 2022, 25(14): 1789-1794. DOI: 10.12114/j.issn.1007-9572.2021.01.039.
Ling LI,Huijuan ZHANG. Recent Developments in Pituitary-directed Medical Treatment for Cushing's Disease[J]. Chinese General Practice, 2022, 25(14): 1789-1794. DOI: 10.12114/j.issn.1007-9572.2021.01.039.

参考文献 48

[1]	PIVONELLO R，DE LEO M，COZZOLINO A，et al. The treatment of Cushing's disease[J]. Endocr Rev，2015，36（4）：385-486. DOI：10.1210/er.2013-1048.
[2]	LUQUE R M，GAHETE M D，HOCHGESCHWENDER U，et al. Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways[J]. Am J Physiol Endocrinol Metab，2006，291（2）：E395-403. DOI：10.1152/ajpendo.00038.2006.
[3]	COLAO A，PETERSENN S，NEWELL-PRICE J，et al. A 12-month phase 3 study of pasireotide in Cushing's disease[J]. N Engl J Med，2012，366（10）：914-924. DOI：10.1056/nejmoa1105743.
[4]	SCHOPOHL J，GU F，RUBENS R，et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease：results from an open-ended，open-label extension trial[J]. Pituitary，2015，18（5）：604-612. DOI：10.1007/s11102-014-0618-1.
[5]	LACROIX A，GU F，GALLARDO W，et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease：a 12 month clinical trial[J]. Lancet Diabetes Endocrinol，2018，6（1）：17-26. DOI：10.1016/s2213-8587(17)30326-1.
[6]	FLESERIU M，PETERSENN S，BILLER B M K，et al. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease：a Phase Ⅲ extension study[J]. Clin Endocrinol：Oxf，2019，91（6）：776-785. DOI：10.1111/cen.14081.
[7]	PAWLIKOWSKI M，KUNERT-RADEK J，STEPIE H. Direct antiproliferative effect of dopamine agonists on the anterior pituitary gland in organ culture[J]. J Endocrinol，1978，79（2）：245-246. DOI：10.1677/joe.0.0790245.
[8]	WANG Y W，LI J Y，TOHTI M，et al. The expression profile of Dopamine D2 receptor，MGMT and VEGF in different histological subtypes of pituitary adenomas：a study of 197 cases and indications for the medical therapy[J]. J Exp Clin Cancer Res，2014，33：56. DOI：10.1186/s13046-014-0056-y.
[9]	FERONE D，PIVONELLO C，VITALE G，et al. Molecular basis of pharmacological therapy in Cushing's disease[J]. Endocrine，2014，46（2）：181-198. DOI：10.1007/s12020-013-0098-5.
[10]	FEELDERS R A，NEWELL-PRICE J，PIVONELLO R，et al. Advances in the medical treatment of Cushing's syndrome[J]. Lancet Diabetes Endocrinol，2019，7（4）：300-312. DOI：10.1016/s2213-8587(18)30155-4.
[11]	PIVONELLO R，DE MARTINO M C，CAPPABIANCA P，et al. The medical treatment of Cushing's disease：effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery[J]. J Clin Endocrinol Metab，2009，94（1）：223-230. DOI：10.1210/jc.2008-1533.
[12]	FERRIERE A，CORTET C，CHANSON P，et al. Cabergoline for Cushing's disease：a large retrospective multicenter study[J]. Eur J Endocrinol，2017，176（3）：305-314. DOI：10.1530/eje-16-0662.
[13]	NAKHLEH A，SAIEGH L，REUT M，et al. Cabergoline treatment for recurrent Cushing's disease during pregnancy[J]. Hormones：Athens，2016，15（3）：453-458. DOI：10.14310/horm.2002.1685.
[14]	FERONE D，GATTO F，ARVIGO M，et al. The clinical-molecular interface of somatostatin，dopamine and their receptors in pituitary pathophysiology[J]. J Mol Endocrinol，2009，42（5）：361-370. DOI：10.1677/jme-08-0162.
[15]	VáZQUEZ-BORREGO M C，L-LóPEZ F，GáLVEZ-MORENO M A，et al. A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells[J]. Neuroendocrinology，2020，110（1/2）：70-82. DOI：10.1159/000500812.
[16]	GüNTHER T，TULIPANO G，DOURNAUD P，et al. International union of basic and clinical pharmacology. CV. somatostatin receptors：structure，function，ligands，and new nomenclature[J]. Pharmacol Rev，2018，70（4）：763-835. DOI：10.1124/pr.117.015388.
[17]	ALBANI A，PEREZ-RIVAS L G，REINCKE M，et al. Pathogenesis of cushing disease：an update on the genetics of corticotropinomas[J]. Endocr Pract，2018，24（10）：907-914. DOI：10.4158/ep-2018-0111.
[18]	LIU N A，JIANG H，BEN-SHLOMO A，et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase （CDK） inhibitor[J]. PNAS，2011，108（20）：8414-8419. DOI：10.1073/pnas.1018091108.
[19]	ARAKI T，LIU N A. Cell cycle regulators and lineage-specific therapeutic targets for cushing disease[J]. Front Endocrinol：Lausanne，2018，9：444. DOI：10.3389/fendo.2018.00444.
[20]	LIU N A，ARAKI T，CUEVAS-RAMOS D，et al. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease[J]. J Clin Endocrinol Metab，2015，100（7）：2557-2564. DOI：10.1210/jc.2015-1606.
[21]	THEODOROPOULOU M，ARZBERGER T，GRUEBLER Y，et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells：evidence for a role in corticotropinoma cells[J]. J Endocrinol，2004，183（2）：385-394. DOI：10.1677/joe.1.05616.
[22]	CHANDRA P，RAJARAM P，TICKU S，et al. Epidermal growth factor receptor：Role in human cancer[J]. Indian J Dent Res，2017，28（6）：687. DOI：10.4103/ijdr.ijdr_534_16.
[23]	TATSI C，FLIPPO C，STRATAKIS C A. Cushing syndrome：Old and new genes[J]. Best Pract Res Clin Endocrinol Metab，2020，34（2）：101418. DOI：10.1016/j.beem.2020.101418.
[24]	PEREZ-RIVAS L G，THEODOROPOULOU M，FERRAù F，et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing's disease[J]. J Clin Endocrinol Metab，2015，100（7）：E997-1004. DOI：10.1210/jc.2015-1453.
[25]	FOULKES E，NEWELL-PRICE J. New molecular targets for treatment of Cushing's disease[J]. Endocrinol Metab Clin North Am，2018，47（2）：367-373. DOI：10.1016/j.ecl.2018.02.006.
[26]	FUKUOKA H，COOPER O，BEN-SHLOMO A，et al. EGFR as a therapeutic target for human，canine，and mouse ACTH-secreting pituitary adenomas[J]. J Clin Invest，2011，121（12）：4712-4721. DOI：10.1172/jci60417.
[27]	SESHACHARYULU P，PONNUSAMY M P，HARIDAS D，et al. Targeting the EGFR signaling pathway in cancer therapy[J]. Expert Opin Ther Targets，2012，16（1）：15-31. DOI：10.1517/14728222.2011.648617.
[28]	ASARI Y，KAGEYAMA K，SUGIYAMA A，et al. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells[J]. Endocr J，2019，66（6）：515-522. DOI：10.1507/endocrj.ej18-0491.
[29]	CIATO D，ALBANI A. Molecular mechanisms of glucocorticoid resistance in corticotropinomas：new developments and drug targets[J]. Front Endocrinol：Lausanne，2020，11：21. DOI：10.3389/fendo.2020.00021.
[30]	RIEBOLD M，KOZANY C，FREIBURGER L，et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease[J]. Nat Med，2015，21（3）：276-280. DOI：10.1038/nm.3776.
[31]	SHEN Y，JI C，JIAN X，et al. Regulation of the EGFR pathway by HSP90 is involved in the pathogenesis of Cushing's disease[J]. Front Endocrinol：Lausanne，2020，11：601984. DOI：10.3389/fendo.2020.601984.
[32]	SALLER R，MEIER R，BRIGNOLI R. The use of silymarin in the treatment of liver diseases[J]. Drugs，2001，61（14）：2035-2063. DOI：10.2165/00003495-200161140-00003.
[33]	SALMANINEJAD A，VALILOU S F，SHABGAH A G，et al. PD-1/PD-L1 pathway：Basic biology and role in cancer immunotherapy[J]. J Cell Physiol，2019，234（10）：16824-16837. DOI：10.1002/jcp.28358.
[34]	HOFMEYER K A，JEON H，ZANG X X. The PD-1/PD-L1 （B7-H1） pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion[J]. J Biomed Biotechnol，2011，2011：451694. DOI：10.1155/2011/451694.
[35]	KEIR M E，BUTTE M J，FREEMAN G J，et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol，2008，26：677-704. DOI：10.1146/annurev.immunol.26.021607.090331.
[36]	WANG P F，WANG T J，YANG Y K，et al. The expression profile of PD-L1 and CD₈⁺ lymphocyte in pituitary adenomas indicating for immunotherapy[J]. J Neurooncol，2018，139（1）：89-95. DOI：10.1007/s11060-018-2844-2.
[37]	KEMENY H R，ELSAMADICY A A，FARBER S H，et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease[J]. Clin Cancer Res，2020，26（5）：1141-1151. DOI：10.1158/1078-0432.CCR-18-3486.
[38]	LIN A L，JONSSON P，TABAR V，et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab[J]. J Clin Endocrinol Metab，2018，103（10）：3925-3930. DOI：10.1210/jc.2018-01347.
[39]	CACCESE M，BARBOT M，CECCATO F，et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab[J]. Anticancer Drugs，2020，31（2）：199-204. DOI：10.1097/cad.0000000000000856.
[40]	SCHRECK K C，GROSSMAN S A. Role of temozolomide in the treatment of cancers involving the central nervous system[J]. Oncology：Williston Park，2018，32（11）：555-560，569.
[41]	SHEEHAN J，RAINEY J，NGUYEN J，et al. Temozolomide-induced inhibition of pituitary adenoma cells[J]. J Neurosurg，2011，114（2）：354-358. DOI：10.3171/2010.4.jns1024.
[42]	RAVEROT G，CASTINETTI F，JOUANNEAU E，et al. Pituitary carcinomas and aggressive pituitary tumours：merits and pitfalls of temozolomide treatment[J]. Clin Endocrinol：Oxf，2012，76（6）：769-775. DOI：10.1111/j.1365-2265.2012.04381.x.
[43]	BROSSAUD J，PALLET V，CORCUFF J B. Vitamin A，endocrine tissues and hormones：interplay and interactions[J]. Endocr Connect，2017，6（7）：R121-130. DOI：10.1530/ec-17-0101.
[44]	CASTILLO V，GIACOMINI D，PA'EZ-PEREDA M，et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs[J]. Endocrinology，2006，147（9）：4438-4444. DOI：10.1210/en.2006-0414.
[45]	PECORI GIRALDI F，AMBROGIO A G，ANDRIOLI M，et al. Potential role for retinoic acid in patients with Cushing's disease[J]. J Clin Endocrinol Metab，2012，97（10）：3577-3583. DOI：10.1210/jc.2012-2328.
[46]	VILAR L，ALBUQUERQUE J L，LYRA R，et al. The role of isotretinoin therapy for Cushing's disease：results of a prospective study[J]. Int J Endocrinol，2016，2016：8173182. DOI：10.1155/2016/8173182.
[47]	ZHANG D，DU L，HEANEY A P. Testicular receptor-4：novel regulator of glucocorticoid resistance[J]. J Clin Endocrinol Metab，2016，101（8）：3123-3133. DOI：10.1210/jc.2016-1379.
[48]	ZHANG D，BERGSNEIDER M，WANG M B，et al. Targeting the ERK pathway for the treatment of Cushing's disease[J]. Oncotarget，2016，7（43）：69149-69158. DOI：10.18632/oncotarget.12381.